Investigational drug · Phase 3
KB803
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "KB803"
First trial start
2025
Jun 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KB803", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dystrophic Epidermolysis Bullosa
- DEB - Dystrophic Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa
- Dominant Dystrophic Epidermolysis Bullosa
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "KB803" as an intervention, largest first.
- A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaPivotal-lookingRecruiting
Krystal Biotech, Inc.Industry
NCT07016750 · 16 participants (planned) · Start Jun 20, 2025 · Primary completion Dec 2026
Drug: KB803; Placebo · For: Dystrophic Epidermolysis Bullosa; DEB - Dystrophic Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa and 1 more
Sites: Rancho Santa Margarita, California; Coral Gables, Florida; Worcester, Massachusetts · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Dystrophic Epidermolysis Bullosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.